NASDAQ$ONC
BeiGene Ltd-ADR · Q3 2020 earnings
Q3 2020 earnings · · Investor relations
Briefing
BeiGene's product revenue increased due to sales of tislelizumab in China and BRUKINSA in the United States and China.
BeiGene reported an increase in product revenue driven by sales of tislelizumab in China and BRUKINSA in the United States and China. The company is focused on expanding its pipeline and commercial opportunities.
- Total product revenue reached $91.08 million, a 81.6% increase compared to the same period last year.
- Sales of tislelizumab in China contributed $49.94 million.
- Sales of BRUKINSA in China and the United States amounted to $15.66 million.
- The company is progressing with clinical trials and regulatory submissions for its drug candidates.
Headline financials
Revenue & EPS history
BeiGene · Revenue · Quarterly
$91.1M
Revenue by segment
BeiGene · $15.7M total across 1 segment · Q3 2020
- BRUKINSA$15.7M—100.0%
Forward guidance
BeiGene anticipates key clinical readouts and potential expanded commercial opportunities for its products through approvals in additional indications and geographic markets.
Tailwinds
- Key clinical readouts expected in the remainder of 2020 and 2021.
- Potential expanded commercial opportunities for products.
- Possible approvals in additional indications and geographic markets.
- Growing commercial-stage portfolio in China to up to 12 products.
- Advancement of pipeline assets, including BGB-11417, BGB-A445, BGB-10188, and BGB-15025.
Headwinds
- COVID-19 pandemic continues to have a negative impact on operations.
- Delays in clinical trial recruitment and data readouts due to COVID-19.
- Uncertainty regarding the future impact of the pandemic in China and the United States.
- Potential delays in regulatory interactions, inspections, and filings.
- Amgen collaboration clinical trials in China are currently delayed.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2020
-0.1%
Avg return
Earnings day
+0.1%
Avg return
5 days after
-2.0%
Avg return
30 days after
40%
16 / 40 earnings
Positive
+15.9%
Q4 2023
Best reaction
-9.6%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +5.3% | +4.3% | -9.4% | |
| Q4 2025 | -8.5% | -15.7% | -19.6% | |
| Q3 2025 | +3.4% | +6.9% | +0.5% | |
| Q1 2025 | -3.9% | -3.5% | +5.8% | |
| Q4 2024 | +7.5% | -0.7% | +3.2% | |
| Q3 2024 | +1.4% | -4.5% | +1.4% | |
| Q2 2024 | +6.8% | +10.9% | +11.7% | |
| Q1 2024 | -2.0% | -2.2% | -4.9% | |
| Q4 2023 | +15.9% | +6.4% | -0.0% | |
| Q3 2023 | -0.5% | +0.7% | -12.6% | |
| Q2 2023 | -0.3% | -9.2% | +1.2% | |
| Q1 2023 | -5.7% | -7.3% | -14.2% | |
| Q4 2022 | +4.2% | +11.9% | +2.9% | |
| Q3 2022 | -0.2% | +7.3% | +4.2% | |
| Q2 2022 | +14.6% | +16.4% | -1.7% | |
| Q1 2022 | -9.6% | -11.9% | -12.9% | |
| Q4 2021 | -2.5% | -0.8% | -10.8% | |
| Q3 2021 | -2.3% | -1.1% | -15.9% | |
| Q2 2021 | -6.3% | -8.1% | -2.0% | |
| Q1 2021 | +2.2% | +5.4% | +15.7% | |
| Q4 2020 | -4.4% | -8.5% | -3.0% | |
| Q3 2020 | -3.6% | -7.2% | -26.8% | |
| Q2 2020 | -2.9% | -7.7% | +5.8% | |
| Q1 2020 | +1.0% | +6.0% | +9.6% | |
| Q4 2019 | -2.3% | -3.2% | -21.8% | |
| Q3 2019 | +2.9% | +3.4% | -6.5% | |
| Q2 2019 | +1.6% | +3.9% | -7.8% | |
| Q1 2019 | +14.2% | +13.6% | +4.3% | |
| Q4 2018 | -2.1% | +8.4% | -5.7% | |
| Q3 2018 | +1.4% | -11.2% | +10.4% | |
| Q2 2018 | -3.7% | -4.4% | -4.7% | |
| Q1 2018 | -5.2% | +4.3% | +20.9% | |
| Q4 2017 | -4.8% | +0.3% | +11.3% | |
| Q3 2017 | -5.5% | -0.0% | +10.4% | |
| Q2 2017 | -7.3% | -9.0% | -7.4% | |
| Q1 2017 | -1.3% | +0.7% | +3.9% | |
| Q4 2016 | -2.8% | -4.1% | -3.1% | |
| Q3 2016 | -4.7% | +7.4% | -19.5% | |
| Q2 2016 | +0.8% | +6.0% | +11.0% | |
| Q4 2015 | +5.9% | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro